Collegium Pharmaceutical (COLL) Common Equity (2014 - 2026)

Collegium Pharmaceutical has reported Common Equity for 13 years, with the latest figure at $311.9 million in Q2 2026.

• On a quarterly basis, Common Equity rose 34.32% year-over-year to $311.9 million in Q2 2026; TTM through Jun 2026 was $311.9 million, a 34.32% increase from a year earlier, with the FY2025 full-year figure at $301.7 million, up 31.83% from the prior year.
• Common Equity was $311.9 million for Q2 2026 at Collegium Pharmaceutical, roughly flat from $312.4 million in the prior quarter.
• The five-year high for Common Equity was $312.4 million in Q1 2026, with the low at $178.9 million in Q3 2023.
• Average Common Equity over 5 years is $228.3 million, with a median of $219.4 million recorded in 2024.
• The sharpest annual moves came in 2022 and 2026: Common Equity slipped 21.91% in 2022, then jumped 34.32% in 2026.
• Over 5 years, Common Equity stood at $194.8 million in 2022, then grew by 0.3% to $195.4 million in 2023, then grew by 17.1% to $228.8 million in 2024, then surged by 31.83% to $301.7 million in 2025, then advanced by 3.39% to $311.9 million in 2026.
• The last three Common Equity figures came in at $311.9 million (Q2 2026), $312.4 million (Q1 2026), and $301.7 million (Q4 2025), per Business Quant data.